Biotech HaemaLogiX – which counts former health minister Greg Hunt as a director – is preparing a 2025 ASX listing, as it ...

We recently compiled a list of the 10 Best Up and Coming Stocks To Buy According to Analysts. In this article, we are going ...

Cryopreservation play Vitrafy and nerve-regeneration house Renerve both listed today, breaking an eight-month drought of life ...

Onyx Biotec’s IPO allotment will be finalised on November 20. The IPO, valued at ₹29.34 crore, opened on November 13 and ...

HanX Biopharmaceuticals is planning a Hong Kong listing to fund the phase 2 trial of its lead solid tumor drug. | HanX ...

Two IPOs are tentatively scheduled to list in the ... After upwardly revising terms and offering more shares at pricing, biotech Septerna (SEPN) raised $288 million at a $797 million market ...

After a decade of significant challenges, biotech's long-term sustainability depends on making fundamental changes to its traditional business model. A commonly held perception in the biotech ...

There were only 36 biotech IPOs last year, compared with 68 in 2015 and a record 85 in 2014 – and a rebound was expected in 2017. Are biotech IPOs back in fashion? | pharmaphorum Skip to main ...

Investors will be watching the success of Jounce’s launch closely, as the last 12 months have seen the market environment for biotech IPOs become less hospitable. Around half of the biotech ...

Legend Biotech is spinning out from parent firm GenScript Biotech to pursue treatments in CAR T cell therapies for multiple myeloma. Legend Biotech is spinning out from parent firm GenScript ...

Going public with a valuation higher than $300 million may now be necessary to attract interest from institutional investors. A few times over the past two decades, a confluence of forces has ...